Abstract
The reproducible and accurate expression of genetic information and the integrity of the human genome, both temporally and topographically, rely heavily on the biochemical ability of nuclear proteins to physically interact with each other, as well as with DNA and RNA, at the molecular level. The strength and specificity of these interactions is primarily determined by the intracellular concentrations of each molecule present. Whereas, the affinity is dictated by the collective primary, secondary, tertiary and quaternary structures of the polypeptides themselves, notwithstanding the intrinsic physicochemical and structural properties of the different types of nucleic acids involved. For the most part, the interactions of DNA with protein molecules occur spontaneously in chromatin because the appropriately folded structures of nuclear proteins are adopted prior to their nucleoplasmic internalization via active and passive transport mechanisms. Once transported into the cell nucleus, most proteins whether, structural in nature, like the histones localized within highly compacted interphase chromatin, or as functional enzymes that modulate chromatin dynamics, such as DNA and RNA polymerases (the catalysts responsible for DNA replication, DNA repair, and transcription) are frequently regulated by unique epigenetic mechanisms of amino acid specific covalent chemical modification, e.g., phosphorylation, acetylation, SUMOylation, nitrosylation, and poly(ADP-ribosyl)ation, just to list a few. Interestingly, while most of these biochemical pathways may be ubiquitous to the cytosolic and plasma membrane compartments, the modification of chromatin proteins via ADP-ribose polymerization, especially when catalyzed by poly(ADP-ribose) polymerases 1 and 2 (PARP-1 and PARP-2), exclusively localizes within the nucleoplasm. Emphasis is placed here to review the current state of the latter, particularly as it pertains to the balance between human health and disease.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Althaus, F.R. (1992). Poly ADP-ribosylation: a histone shuttle mechanism in DNA excision repair. J. Cell Sci. 102:663–670.
Alvarez-Gonzalez, R., Juarez-Salinas, H., Jacobson, E.L., et al. (1983). Evaluation of immobilized boronates for studies of adenine and pyridine nucleotide metabolism. Anal. Biochem. 135:69–77.
Alvarez-Gonzalez, R., and Jacobson, M.K. (1987). Characterization of polymers of adenosine diphosphate ribose generated in Vitro and in Vivo. Biochemistry 26:3218–3224.
Alvarez-Gonzalez, R. (1988). 3′-deoxyNAD as a substrate for poly(ADP-ribose) polymerase and the reaction mechanism of poly(ADP-ribose) elongation. J. Biol. Chem. 263: 17690–17696.
Alvarez-Gonzalez, R. (ed) (1999). ADP-ribosylation reactions: from bacterial pathogenesis to cancer. Kluwer, Dordrecht/Boston/London.
Alvarez-Gonzalez, R., Spring, H., Muller, M., et al. (1999). Selective loss of poly(ADP-ribose) and the 85 kDa fragment of poly(ADP-ribose) polymerase in nucleoli during alkylation-induced apoptosis in HeLa cells. J. Biol. Chem. 274:32122–32126.
Alvarez-Gonzalez, R. (2001). PARP-regulation of eukaryotic gene expression. Survival or Death? Trends Genet. 17:607–608.
Alvarez-Gonzalez, R. (2007). Genomic maintenance: the p53 poly(ADP-ribosyl)ation connection. Sci. STKE (415):pe68.
Atorino, L., Alvarez-Gonzalez, R., Cardone, A., et al. (2000). Metabolic changes in the poly(ADP-ribosyl)ation pathway of differentiating rat germinal cells. Arch. Biochem. Biophys. 381:111–118.
Bartha, E., Kiss, G.N., Kalman, E., et al. (2008). Effect of L-2286, a poly(ADP-ribose) polymerase inhibitor and enalapril on myocardial remodeling and heart failure. J. Cardiovasc. Pharmacol. 52:253–261.
Beneke, S., and Burkle, A. (2007). Poly(ADP-ribosyl)ation in mammalian aging. Nucleic Acids Res. 35:7456–7465.
Benjamin, R.C., and Gill, D.M. (1980). ADP-ribosylation in mammalian cell ghosts. Dependence of poly(ADP-ribose) synthesis on strand breakage on DNA. J. Biol. Chem. 255:10493–10501.
Beard, W.A., and Wilson, S.H. (2006). Structure and mechanism of DNA polymerase beta. Chem. Rev. 106:361–382.
Booz, G.W. (2007). PARP inhibitors and heart failure. Translational medicine caught in the act. Congestive Heart Fail. 13:105–112.
Bouchard, V.J., Rouleau, M., Poirier, G.G. (2003). PARP-1, a determinant of cell survival in response to DNA damage. Exp. Hematol. 31:446–454.
Bromme, H.J., and Holtz, J. (1996). Apoptosis in the heart: when and why. Mol. Cell. Biochem. 163–164:261–275.
Chambon, P., Weill, J.D., Mandel, P. (1963). Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing enzyme. Biochem. Biophys. Res. Commun. 11:9–43.
Chang, W.J., and Alvarez-Gonzalez, R. (2001). The sequence specific DNA-binding of NF-κB is reversibly regulated by the automodification reaction of poly(ADP-ribose) polymerase-1. J. Biol. Chem. 276:47664–47670.
Chatteerjee, S., Berger, S.J., Berger, N.A. (1999). Poly(ADP-ribose) polymerase: a guardian of the genome that facilitates DNA repair by protecting against DNA recombination. Mol. Cell. Biochem. 193:23–30.
Choi, D.W. (1997). At the scene of ischemic brain injury. Is PARP a perp. Nature (Med) 3:1073–1074.
Conde, C., Mark, M., Oliver, F.J., Huber, A., et al. (2001). Loss of poly(ADP-ribose) polymerase 1 causes increased tumor latency in p53 deficient mice. EMBO J. 20:3535–3543.
Csiszar, A., Wang, M., Lakkata, E.G., et al. (2008). Inflammation and endothelial dysfunction during aging: role of NF-kappa B. J. Appl. Physiol. 105:1333–1341.
De Boer, R.A., van Veldhuisen, D.J., van der Wijk, J., et al. (2000). Additional use of immunostaining for active caspase 3 and cleaved actin and PARP fragments to detect apoptosis in patients with chronic heart failure. J. Card. Fail. 6:330–337.
Donawho, C.K., Luo, Y., Penning, T.D., et al. (2007). ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in pre-clinical tumor models. Clin. Cancer Res. 13:2728–2737.
El-Domyati, M.M., Al-Din, A.B., Barakat, M.T., et al. (2008). Deoxyribonucleic acid repair and apoptosis in testicular germ cells of aging fertile men: the role of the poly(adenosine diphosphate ribosyl)ation pathway. Fertil. Steril. 91(Suppl 5):2221–2229
Endres, M., Wang, Z.Q., Namura, S., et al. (1997). Ischemic brain injury is mediated by the activation by poly(ADP-ribose) polymerase. J. Cereb. Blood Flow Metab. 17:1143–1151.
Gospodinov, A., and Herceg, Z. (2009). Chromatin. The entry and exit from DNA repair. In: Vidal, C.J. (ed) Post-translational Modifications of Proteins, Springer, New York.
Grube, K., and Burkle, A. (1992). Poly(ADP-ribose) polymerase activity in mononuclear leukocytes of 13 mammalian species correlates with species-specific life span. Proc. Natl. Acad. Sci. U.S.A. 89:11759–11763.
Haddad, M., Beray-Berthat, V., Coqueran, B., et al. (2008). Reduction of hemorrhagic transformation by PJ34, a poly(ADP-ribose) polymerase inhibitor after permanent focal cerebral ischemia in mice. Eur. J. Pharmacol. 588:52–57.
Hassa, P.O., Buerki, C., Lombardi, C., et al. (2003). Transcriptional co-activation of nuclear factor-κB-dependent gene expression by p300 is regulated by poly(ADP-ribose) polymerase-1. J. Biol. Chem. 278:45145–45153.
Izzo, A., Kamieniarz, K., Schneider, R. (2008). The histone H1 family: specific members, specific functions? Biol. Chem. 389:333–343.
Jeoung, D., Lim, Y., Lee, E.B., et al. (2004). Identification of autoantibody against poly(ADP-ribose) polymerase (PARP) fragment as a serological marker in systemic lupus erythematosus. J. Autoimmunity 22: 87–94.
Joashi, U.C., Greenwood, K., Taylor, D.L., et al. (1999). Poly(ADP-ribose) polymerase cleavage precedes neuronal cell death in the hippocampus and cerebellum following injury to the development rat forebrain. Eur. J. Neurosci. 11:91–100.
Juarez-Salinas, H., Sims, J.L., Jacobson, M.K. (1979). Poly(ADP-ribose) levels in carcinogen-treated cells. Nature (London) 282:740–741.
Kawaichi, K., Ueda, K., Hayaishi, O. (1981). Multiple autopoly(ADP-ribosyl)ation of rat liver poly(ADP-ribose) synthetase: Mode of modification and properties of automodified synthetase. J. Biol. Chem. 256:9483–9489.
Kouzarides, T. (2007). Chromatin modifications and their function. Cell 128:693–705.
Kumari, S.R., Alvarez-Gonzalez, R., Mendoza-Alvarez, H. (1998). Functional interactions of p53 with poly(ADP-ribose) polymerase (PARP) during apoptosis following DNA-damage: covalent poly(ADP-ribosyl)ation by exogenous PARP and non-covalent binding of p53 to Mr 85,000 proteolytic fragment. Cancer Res. 58:5075–5078.
Lane, D.P. (1992). Cancer. p53- Guardian of the genome. Nature (London) 358:15–16.
Lindall, A.W., and Lazarow, L. (1964). A critical study of pyridine nucleotide concentrations in normal fed, normal fasted and diabetic rat liver. Metabolism 13:259–271.
Loetscher, P., Alvarez-Gonzalez, R., Althaus, F.R. (1987). Poly(ADP-ribose) may signal changing metabolic conditions to the chromatin of mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 84: 1286–1289.
Malecka, K.A., Ho, W.C., Marmorstein, R. (2009). Crystal structure of a p53 core tetramer bound to DNA. Oncogene 28:325–333.
Masutani, M., Suzuki, H., Kamada, N., et al. (1999). Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptosotocyn-induced diabetes. Proc. Natl. Acad. Sci. U.S.A. 96:2301–2304.
Mendoza-Alvarez, H., and Alvarez-Gonzalez, R. (1993). Poly(ADP-ribose) polymerase is a catalytic dimer and the automodification reaction is intermolecular. J. Biol. Chem. 268:22575–22580.
Mendoza-Alvarez, H., and Alvarez-Gonzalez, R. (2001). Regulation of p53 sequence-specific binding by covalent poly(ADP-ribosyl)ation. J. Biol. Chem. 276:36425–36430.
Mendoza-Alvarez, H., and Alvarez-Gonzalez, R. (1999). Biochemical characterization of mono(ADP-ribosyl)ated poly(ADP-ribose) polymerase. Biochemistry 38:3948–3953.
Messmer, U.K., Winkel, G., Briner, G.A., et al. (2000). Suppression of apoptosis by glucocorticoids in glomerulal endothelial cells: effects on proapoptotic pathways. Br. J. Pharmacol. 29:1673–1683.
Molnar. A., Toth, A., Bagi, Z., et al. (2006). Activation of the poly(ADP-ribose) polymerase pathway in human heart failure. Mol. Med. 12:143–152.
Moroni, F., and Chiarugi, A. (2009). Post-ischemic brain damage: targeting PARP-1 within the ischemic neurovascular units as a realistic avenue to stroke treatment. FEBS J. 276:36–45.
Negri, C., Scovassi, A.I., Cerino, A., et al. (1990). Autoantibodies to poly(ADP-ribose) polymerase in autoimmune diseases. Autoimmunity 6:203–209.
Oliver, F.J., Menissier-de Murcia, J., Nacci, C., et al. (1999). Resistance to endotoxic shock as a consequence to defective NF-κB activation in poly(ADP-ribose) polymerase-1 deficient mice. EMBO J. 18:4446–4454.
Okamoto, H. (1999). The CD38-cyclic ADP-ribose signaling system in insulin secretion. Mol. Cell. Biochem. 193:115–118.
Pacheco-Rodriguez, G., and Alvarez-Gonzalez, R. (1999). Measurement of poly(ADP-ribose) glycohydrolase activity by high resolution polyacrylamide gel electrophoresis: specific inhibition by histones and nuclear matrix proteins. Mol. Cell. Biochem. 193:13–18.
Pacher, P., and Szabo, C. (2008). Role of peroxynitrate-poly(ADP-ribose) polymerase pathway in human disease. Am. J. Pathol. 173:1–13.
Perkin, N.D., and Gilmore, T.D. (2006). Good cop, bad cop: the different faces of NF-kappa B. Cell Death Differ. 13:759–772.
Pietsch, E.C., Sykes, S.M., MacMahon, S.B., et al. (2008). The p53 family and programmed cell death. Oncogene 27:6507–6521.
Pillai, J.B., Isbatan, A., Imai, S.I., et al. (2005). Poly(ADP-ribose) polymerase 1-dependent cardiac myocyte cell death during heart failure is mediated by NAD + cell depletion and reduced Sir2α deacetylase activity. J. Biol. Chem. 280:43121–43130.
Plummer, R., Jones, C., Middleton, M., et al. (2008). Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG-14699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer. Res. 14:7917–7923.
Rosen, A., and Casciola-Rosen, L. (2004). Altered autoantigen structure in Sjogren’s syndrome: implications for the pathogenesis of autoimmune tissue damage. Crit. Rev. Oral Biol. Med. 15:156–164.
Scovassi, A.I., and Poirier, G.G. (1999). Poly(ADP-ribosyl)ation and apoptosis. Mol. Cell. Biochem. 199:125–137.
Simbulan-Rosenthal, C.M., Rosenthal, D.S., Luo, R. B., et al. (2001). Poly(ADP-ribosyl)ation of p53 in vitro and in vivo modulates binding to its DNA consensus sequence. Neoplasia 3:179–188.
Suganuma, T., and Workman, J.L. (2008). Crosstalk among histone modifications. Cell 135:604–607.
Tong, W.M., Cortes, U., Wang, Z.Q. (2001). Poly(ADP-ribose) polymerase: a guardian angel protecting the genome and suppressing tumorigenesis. Biochim. Biophys. Acta 1552:27–37.
Tremethik, D.J. (2007). Higher-ordered structures of chromatin: the elusive 30 nm fiber. Cell 128:651–654.
Tye, B.K., and Swayer, S. (2000). The hexameric eukaryotic MCM helicase: building symmetry from non-identical parts. J. Biol. Chem. 275:34833–34836.
Valdor, R., Schreiber, V., Saenz, J., et al. (2008). Regulation of NFAT by poly(ADP-ribose) polymerase in T cells. Mol. Immunol. 24:1863–1871.
Wieler, S., Cagne, J.P., Vaziri, H., et al. (2003). Poly(ADP-ribose) polymerase-1 is a positive regulator of the p53-mediated G1 cycle arrest response following ionizing radiation. J. Biol. Chem. 278:18914–18921.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Alvarez-Gonzalez, R. (2011). Poly(ADP-Ribosyl)ation of Chromosomal Proteins, Epigenetic Regulation and Human Genomic Integrity in Health and Disease. In: Vidal, C. (eds) Post-Translational Modifications in Health and Disease. Protein Reviews, vol 13. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-6382-6_17
Download citation
DOI: https://doi.org/10.1007/978-1-4419-6382-6_17
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4419-6381-9
Online ISBN: 978-1-4419-6382-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)